Drug intelligence / Profile preview

NX-CP105

Development stage: Phase 1
Lead developer: Neuronyx
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intracoronary, Intradermal, Intramyocardial, Topical

Overview

NX-CP105 is an allogeneic cell therapy product consisting of human adult bone marrow-derived somatic cells (hABM-SC). Developed by Neuronyx, Inc., the therapy was designed to treat patients who have recently suffered an acute myocardial infarction (AMI). The treatment involves the direct delivery of these somatic cells into the heart muscle via endomyocardial injection, with the goal of promoting tissue repair and improving cardiac function following injury. Clinical development reached Phase 1 testing but was subsequently terminated.

Other names: hABM-SCHuman Adult Bone Marrow Derived Somatic Cells

Beyond the preview

Go deeper on NX-CP105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NX-CP105.

Explore the full profile